Abstract
Introduction
The cytotoxics market is mature and characterized by an increasing level of
genericization. Several blockbuster products will undergo patent expiry during
the forecast period, however, by virtue of these drugs' success, generic entry
will ensure continued growth. Coupled with the launch of several new brands,
steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Key reasons to purchase this research
- Quantify the performance of each of the marketed cytotoxic therapy cancer
brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and
the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and
rest of class and align their 7MM performance with a rest of world snapshot
| 
View Cart
